How Does Psilocybin Work in the Brain? The Neuroscience Explained

Psilocybin is a prodrug. The molecule you ingest is not the active one. Alkaline phosphatase — an enzyme present in the gut wall, intestinal mucosa, and blood — cleaves the phosphate group from psilocybin and produces psilocin. Psilocin is what enters the brain, binds to serotonin receptors, and produces every effect associated with "magic mushrooms." Understanding this conversion is the starting point for understanding the entire mechanism.

The Prodrug Conversion

The conversion from psilocybin to psilocin is pharmacologically elegant for one specific reason: psilocybin is orally bioavailable and chemically stable, while psilocin is not.

Psilocin degrades rapidly under heat, light, and oxidizing conditions. Psilocybin does not. By carrying the active molecule in a stable phosphorylated form and relying on ubiquitous bodily enzymes to activate it at the point of use, the compound solves a delivery problem that synthetic chemists work around with considerable effort.

First-pass metabolism in the liver further processes psilocin, but a substantial fraction reaches systemic circulation and crosses the blood-brain barrier. The conversion happens primarily in the gut and blood, with the liver contributing additional dephosphorylation. Peak plasma psilocin concentrations are typically reached within 60–90 minutes of oral ingestion.

5-HT2A Receptor Agonism

Psilocin is a partial agonist at the 5-HT2A serotonin receptor — the primary receptor mediating its psychedelic effects. The 5-HT2A receptor is a G-protein coupled receptor that normally responds to serotonin. Psilocin's structural similarity to serotonin (both are tryptamines) allows it to occupy the same binding site with approximately 6-fold greater effective affinity at the 5-HT2A subtype.

The receptor is not evenly distributed throughout the brain. It is most concentrated in the cerebral cortex, particularly in Layer V pyramidal neurons — the large excitatory neurons whose long axons project broadly and coordinate activity across cortical regions. These neurons are gatekeepers of high-level integration. When psilocin binds here in quantity, it doesn't simply activate them — it alters how they respond to incoming signals, changing the computational character of their output.

5-HT2A activation in cortical pyramidal neurons increases glutamate release, producing a cascade of downstream excitation. This is not a sedative mechanism. It is an activating one — which is consistent with the phenomenology of a psilocybin experience, in which the brain does not quiet but reorganizes.

The Default Mode Network Suppression Cascade

The default mode network (DMN) is a set of brain regions — including the medial prefrontal cortex, posterior cingulate cortex, and angular gyrus — that are most active when the brain is at rest and suppressed during externally directed tasks. Its primary function is self-referential processing: the narrative sense of self, autobiographical memory, future projection, the running monologue of identity.

Under full-dose psilocybin, fMRI studies consistently show 25–30% reductions in DMN activity. This is not a side effect — it appears to be mechanistically central to the therapeutic and phenomenological effects.

The suppression likely arises through two converging pathways. First, direct 5-HT2A-mediated disruption of the posterior cingulate cortex and medial prefrontal regions — areas both DMN-central and heavily populated with 5-HT2A receptors. Second, altered thalamocortical gating: the thalamus normally filters and routes sensory information, acting as a gatekeeper that maintains the brain's ordinary signal hierarchy. Psilocin's cortical effects appear to loosen this filtering, allowing unusual cross-network connectivity that displaces DMN dominance.

The practical consequence is the softening or dissolution of the ordinary sense of self — ego dissolution at high doses. This is not metaphorical loosening. It is measurable suppression of the neural substrate of self-referential processing.

Increased Neural Entropy and the REBUS Model

Psilocybin increases what researchers measure as neural entropy — the diversity and unpredictability of brain activity patterns. Under ordinary conditions, the brain operates with strong top-down constraints: prior beliefs, expectations, and habitual processing patterns shape what information gets amplified and what gets filtered. The result is efficient but constrained.

Under psilocybin, those constraints relax. Brain activity patterns become more diverse. Networks that don't normally communicate begin exchanging signals. The brain temporarily explores a larger portion of its possible state space.

The brain temporarily operates with higher dimensional complexity. The normal hierarchy of processing flattens — not into disorganization, but into hyper-organization at a different level. Ordinary consciousness is efficient precisely because it is constrained. Psilocybin is what happens when those constraints are selectively released.

Carhart-Harris and colleagues formalized this as the REBUS model — Relaxed Beliefs Under Psychedelics. The proposal is that psychedelics flatten the brain's predictive hierarchy, reducing the dominance of top-down priors and temporarily making perception and cognition more data-driven. Maladaptive patterns — rigid beliefs, entrenched emotional responses, repetitive thought loops — are hierarchical structures. Flattening the hierarchy creates a window in which those structures are less fixed.

The BDNF and Neuroplasticity Window

BDNF — brain-derived neurotrophic factor — is a protein that promotes the survival, growth, and differentiation of neurons and synapses. It is the primary molecular signal for synaptic plasticity: the ability of neural connections to strengthen, weaken, or reorganize.

Psilocin administration in preclinical models produces acute increases in BDNF expression of approximately 50% in prefrontal and hippocampal tissue. Separately, preclinical research from David Olson's lab at UC Davis has shown that psilocin and other psychedelics promote dendritic spine growth — the physical extension of synaptic connections — in cortical neurons. This structural change is measurable, and it persists.

The practical implication is that the period following a psilocybin session is not passive recovery. The brain is in a state of elevated plasticity — more capable of forming new connections, more susceptible to the strengthening of recently activated pathways.

This is why set and setting matter mechanistically, not just psychologically. Whatever content dominates the experience — whatever insights, emotional resolutions, or behavioral intentions are held during the neuroplasticity window — has disproportionate access to the synaptic machinery for encoding. Integration practices during the post-session window are not optional enrichment. They are mechanistically load-bearing.

Why the Mechanism Is Not Blunt

Every step of the psilocybin mechanism is specific. The prodrug form selects for oral administration and gut/blood activation. Psilocin selectively targets 5-HT2A over the dozens of other serotonin receptor subtypes. 5-HT2A is most concentrated in the cortical Layer V neurons that coordinate high-level integration. DMN suppression follows from cortical 5-HT2A activation through a defined pathway. The BDNF response opens a time-limited plasticity window during which the experience content can be neurally consolidated.

This is not a molecule that produces nonspecific brain perturbation. It is a compound with multiple layers of specificity, each pointing at the same functional target: the loosening of entrenched neural hierarchies and the opening of a window for reorganization.

Related: What Is Psilocybin? The Complete Guide · Ego Dissolution — The Neuroscience · Technospermia — The Core Argument